Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-ACT: Prevention of De Novo HCV Post-Transplant
NCT03619837Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of velpatasvir in hepatitis C (HCV), sponsored by University of California, San Francisco. Primary endpoint: Proportion of Participants With HCV RNA Level Below Limits of Quantification. Started Jul 2018; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03619837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619837.